UBS Group
ODTX icon

UBS Group’s Odyssey Therapeutics ODTX Stock Holding History

UBS Group’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$31.5K Sell
1,416
-67,342
-98% -$1.43M ﹤0.01% 8061
2026
Q2 		$1.29M Buy
+68,758
New +$1.21M ﹤0.01% 5512

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lightspeed Management Company
Lightspeed Management Company Menlo Park, California $2.03B AUM 10.68% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group's ODTX Position: Q3 2026 in Review

UBS Group reduced its Odyssey Therapeutics (ODTX) stake by 98% in Q3 2026, selling an estimated $1.43M and leaving 1,416 shares worth $31.5K. The position accounts for ﹤0.01% of the portfolio, ranked #8061.

UBS Group first reported a position in ODTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.29M in Q2 2026. 41 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

  • UBS Group held 1,416 shares of Odyssey Therapeutics worth $31.5K as of Q3 2026.
  • UBS Group sold 67,342 Odyssey Therapeutics shares in Q3 2026, an estimated $1.43M.
  • Odyssey Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8061 holding.
  • UBS Group first reported a position in Odyssey Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • UBS Group's Odyssey Therapeutics position peaked at $1.29M in Q2 2026.
  • 41 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.